Currently, the most successful example of pharmacogenetics in ALL in a clinical setting is the detection of genetic variants of genes encoding TPMT and NUDT enzymes prior to the prescription of thiopurine drugs and, although it has been implemented in different parts of our country, hematologic toxicity still occurs with high frequency (28). The gene discussed is TPMT; the disease is acute lymphoblastic leukemia.